Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide

Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vitro and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobola, Michael S., Kolstoe, Douglas D., Blank, A., Chamberlain, Marc C., Silber, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515961/
https://www.ncbi.nlm.nih.gov/pubmed/23230562
http://dx.doi.org/10.3389/fonc.2012.00176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515961/
https://www.ncbi.nlm.nih.gov/pubmed/23230562
http://dx.doi.org/10.3389/fonc.2012.00176

Ejemplares similares